Genentech, a member of the Roche Group, announced on Oct. 22nd, 2021, that FDA had approved Susvimo (100 mg/mL ranibizumab injection) for the treatment of wet, or neovascular, age-related macular degeneration (AMD), a condition that can lead to rapid and severe loss of vision. Susvimo is approved for intravitreal use via ocular implant for patients who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
